|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–109. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Van Meir EG, Hadjipanayis CG, Norden AD,
Shu HK, Wen PY and Olson JJ: Exciting new advances in
neuro-oncology: The avenue to a cure for malignant glioma. CA
Cancer J Clin. 60:166–193. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Willert K and Nusse R: Wnt proteins. Cold
Spring Harb Perspect Biol. 4:a0078642012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yu J and Virshup DM: Updating the Wnt
pathways. Biosci Rep. 34:pii: e001422014. View Article : Google Scholar
|
|
7
|
MacDonald BT, Tamai K and He X:
Wnt/beta-catenin signaling: Components, mechanisms, and diseases.
Dev Cell. 17:9–26. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Baarsma HA, Königshoff M and Gosens R: The
WNT signaling pathway from ligand secretion to gene transcription:
Molecular mechanisms and pharmacological targets. Pharmacol Ther.
138:66–83. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Polakis P: Wnt signaling in cancer. Cold
Spring Harb Perspect Biol. 4:pii: a0080522012. View Article : Google Scholar
|
|
10
|
Zhang K, Zhang J, Han L, Pu P and Kang C:
Wnt/beta-catenin signaling in glioma. J Neuroimmune Pharmacol.
7:740–749. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Anastas JN and Moon RT: WNT signalling
pathways as therapeutic targets in cancer. Nat Rev Cancer.
13:11–26. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kaur N, Chettiar S, Rathod S, Rath P,
Muzumdar D, Shaikh ML and Shiras A: Wnt3a mediated activation of
Wnt/β-catenin signaling promotes tumor progression in glioblastoma.
Mol Cell Neurosci. 54:44–57. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Reis M, Czupalla CJ, Ziegler N, Devraj K,
Zinke J, Seidel S, Heck R, Thom S, Macas J, Bockamp E, et al:
Endothelial Wnt/β-catenin signaling inhibits glioma angiogenesis
and normalizes tumor blood vessels by inducing PDGF-B expression. J
Exp Med. 209:1611–1627. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kamino M, Kishida M, Kibe T, Ikoma K,
Iijima M, Hirano H, Tokudome M, Chen L, Koriyama C, Yamada K, et
al: Wnt-5a signaling is correlated with infiltrative activity in
human glioma by inducing cellular migration and MMP-2. Cancer Sci.
102:540–548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Klein D, Demory A, Peyre F, Kroll J,
Augustin HG, Helfrich W, Kzhyshkowska J, Schledzewski K, Arnold B
and Goerdt S: Wnt2 acts as a cell type-specific, autocrine growth
factor in rat hepatic sinusoidal endothelial cells
cross-stimulating the VEGF pathway. Hepatology. 47:1018–1031. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Azzolin L, Zanconato F, Bresolin S,
Forcato M, Basso G, Bicciato S, Cordenonsi M and Piccolo S: Role of
TAZ as mediator of Wnt signaling. Cell. 151:1443–1456. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pu P, Zhang Z, Kang C, Jiang R, Jia Z,
Wang G and Jiang H: Downregulation of Wnt2 and beta-catenin by
siRNA suppresses malignant glioma cell growth. Cancer Gene Ther.
16:351–361. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu X, Wang L, Zhao S, Ji X, Luo Y and
Ling F: β-Catenin overexpression in malignant glioma and its role
in proliferation and apoptosis in glioblastma cells. Med Oncol.
28:608–614. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi Z, Qian X, Li L, Zhang J, Zhu S, Zhu
J, Chen L, Zhang K, Han L, Yu S, et al: Nuclear translocation of
β-catenin is essential for glioma cell survival. J Neuroimmune
Pharmacol. 7:892–903. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fu L, Zhang C, Zhang LY, Dong SS, Lu LH,
Chen J, Dai Y, Li Y, Kong KL, Kwong DL and Guan XY: Wnt2 secreted
by tumour fibroblasts promotes tumour progression in oesophageal
cancer by activation of the Wnt/β-catenin signalling pathway. Gut.
60:1635–1643. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zheng D, Decker KF, Zhou T, Chen J, Qi Z,
Jacobs K, Weilbaecher KN, Corey E, Long F and Jia L: Role of
WNT7B-induced noncanonical pathway in advanced prostate cancer. Mol
Cancer Res. 11:482–493. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
You L, He B, Xu Z, Uematsu K, Mazieres J,
Mikami I, Reguart N, Moody TW, Kitajewski J, McCormick F and
Jablons DM: Inhibition of Wnt-2-mediated signaling induces
programmed cell death in non-small-cell lung cancer cells.
Oncogene. 23:6170–6174. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mazieres J, You L, He B, Xu Z, Twogood S,
Lee AY, Reguart N, Batra S, Mikami I and Jablons DM: Wnt2 as a new
therapeutic target in malignant pleural mesothelioma. Int J Cancer.
117:326–332. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
You L, He B, Xu Z, Uematsu K, Mazieres J,
Fujii N, Mikami I, Reguart N, McIntosh JK, Kashani-Sabet M, et al:
An anti-Wnt-2 monoclonal antibody induces apoptosis in malignant
melanoma cells and inhibits tumor growth. Cancer Res. 64:5385–5389.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Katoh M: WNT2B: Comparative integromics
and clinical applications (Review). Int J Mol Med. 16:1103–1108.
2005.PubMed/NCBI
|
|
27
|
Liu D, Kadota K, Ueno M, Nakashima N,
Yokomise H and Huang Cl: Adenoviral vector expressing short hairpin
RNA targeting Wnt2B has an effective antitumour activity against
Wnt2B2-overexpressing tumours. Eur J Cancer. 48:1208–1218. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Arensman MD, Kovochich AN, Kulikauskas RM,
Lay AR, Yang PT, Li X, Donahue T, Major MB, Moon RT, Chien AJ and
Dawson DW: WNT7B mediates autocrine Wnt/β-catenin signaling and
anchorage-independent growth in pancreatic adenocarcinoma.
Oncogene. 33:899–908. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yeo EJ, Cassetta L, Qian BZ, Lewkowich I,
Li JF, Stefater JA III, Smith AN, Wiechmann LS, Wang Y, Pollard JW
and Lang RA: Myeloid WNT7b mediates the angiogenic switch and
metastasis in breast cancer. Cancer Res. 74:2962–2973. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Salsano E, Paterra R, Figus M, Menghi F,
Maderna E, Pollo B, Solero CL, Massimi L and Finocchiaro G:
Expression profile of frizzled receptors in human medulloblastomas.
J Neurooncol. 106:271–280. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Da Forno PD, Pringle JH, Hutchinson P,
Osborn J, Huang Q, Potter L, Hancox RA, Fletcher A and Saldanha GS:
WNT5A expression increases during melanoma progression and
correlates with outcome. Clin Cancer Res. 14:5825–5832. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fernandez-Cobo M, Zammarchi F, Mandeli J,
Holland JF and Pogo BG: Expression of Wnt5A and Wnt10B in
non-immortalized breast cancer cells. Oncol Rep. 17:903–907.
2007.PubMed/NCBI
|
|
33
|
Ripka S, König A, Buchholz M, Wagner M,
Sipos B, Klöppel G, Downward J, Gress T and Michl P: WNT5A-target
of CUTL1 and potent modulator of tumor cell migration and invasion
in pancreatic cancer. Carcinogenesis. 28:1178–1187. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang Q, Williamson M, Bott S,
Brookman-Amissah N, Freeman A, Nariculam J, Hubank MJ, Ahmed A and
Masters JR: Hypomethylation of WNT5A, CRIP1 and S100P in prostate
cancer. Oncogene. 26:6560–6565. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yu JM, Jun ES and Jung JS, Suh SY, Han JY,
Kim JY, Kim KW and Jung JS: Role of Wnt5a in the proliferation of
human glioblastoma cells. Cancer Lett. 257:172–181. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Torres MA, Yang-Snyder JA, Purcell SM,
DeMarais AA, McGrew LL and Moon RT: Activities of the Wnt-1 class
of secreted signaling factors are antagonized by the Wnt-5A class
and by a dominant negative cadherin in early Xenopus development. J
Cell Biol. 133:1123–1137. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Olson DJ and Gibo DM: Antisense wnt-5a
mimics wnt-1-mediated C57MG mammary epithelial cell transformation.
Exp Cell Res. 241:134–141. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ishitani T, Kishida S, Hyodo-Miura J, Ueno
N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J and
Matsumoto K: The TAK1-NLK mitogen-activated protein kinase cascade
functions in the Wnt-5a/Ca(2+) pathway to antagonize
Wnt/beta-catenin signaling. Mol Cell Biol. 23:131–139. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Topol L, Jiang X, Choi H, Garrett-Beal L,
Carolan PJ and Yang Y: Wnt-5a inhibits the canonical Wnt pathway by
promoting GSK-3-independent beta-catenin degradation. J Cell Biol.
162:899–908. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nemeth MJ, Topol L, Anderson SM, Yang Y
and Bodine DM: Wnt5a inhibits canonical Wnt signaling in
hematopoietic stem cells and enhances repopulation. Proc Natl Acad
Sci USA. 104:pp. 15436–15441. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yuzugullu H, Benhaj K, Ozturk N, Senturk
S, Celik E, Toylu A, Tasdemir N, Yilmaz M, Erdal E, Akcali KC, et
al: Canonical Wnt signaling is antagonized by noncanonical Wnt5a in
hepatocellular carcinoma cells. Mol Cancer. 8:902009. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pourreyron C, Reilly L, Proby C,
Panteleyev A, Fleming C, McLean K, South AP and Foerster J: Wnt5a
is strongly expressed at the leading edge in non-melanoma skin
cancer, forming active gradients, while canonical Wnt signalling is
repressed. PLoS One. 7:e318272012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gujral TS, Chan M, Peshkin L, Sorger PK,
Kirschner MW and MacBeath G: A noncanonical Frizzled2 pathway
regulates epithelial-mesenchymal transition and metastasis. Cell.
159:844–856. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Yu M, Ting DT, Stott SL, Wittner BS,
Ozsolak F, Paul S, Ciciliano JC, Smas ME, Winokur D, Gilman AJ, et
al: RNA sequencing of pancreatic circulating tumour cells
implicates WNT signalling in metastasis. Nature. 487:510–513. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Miyamoto DT, Zheng Y, Wittner BS, Lee RJ3,
Zhu H, Broderick KT, Desai R, Fox DB, Brannigan BW, Trautwein J, et
al: RNA-Seq of single prostate CTCs implicates noncanonical Wnt
signaling in antiandrogen resistance. Science. 349:1351–1356. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Zhan T, Rindtorff N and Boutros M: Wnt
signaling in cancer. Oncogene. 36:1461–1473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Yano H, Hara A, Shinoda J, Takenaka K,
Yoshimi N, Mori H and Sakai N: Immunohistochemical analysis of
beta-catenin in N-ethyl-N-nitrosourea-induced rat gliomas:
Implications in regulation of angiogenesis. Neurol Res. 22:527–532.
2000.PubMed/NCBI
|
|
48
|
Wang Z and Chen Q: β-catenin knockdown
inhibits the proliferation of human glioma cells in vitro and in
vivo. Exp Ther Med. 11:1059–1064. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Rossi M, Magnoni L, Miracco C, Mori E,
Tosi P, Pirtoli L, Tini P, Oliveri G, Cosci E and Bakker A:
β-catenin and Gli1 are prognostic markers in glioblastoma. Cancer
Biol Ther. 11:753–761. 2011. View Article : Google Scholar : PubMed/NCBI
|
